Sobi springboards U.S. growth in deal for AZ's Synagis

Swedish Orphan Biovitrum AB (SSE:SOBI) obtained U.S. rights to commercialize infectious disease drug Synagis palivizumab from AstraZeneca plc (LSE:AZN; NYSE:AZN) for $1.5 billion up front. Sobi called the deal, which also includes profit sharing with the pharma for MEDI8897, a stepping stone

Read the full 421 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE